SCHEMBL3117644

SCHEMBL3117644

CC(C)c1ccc(C=O)cc1C=O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TYR P14679 2/20 0.48
ALDH1A1 P00352 8/20 0.41
ALDH1A3 P47895 2/20 0.39
TSHR P16473 1/20 0.39
KDM4E B2RXH2 2/20 0.39
PTGS2 P35354 1/20 0.39
RAB9A P51151 1/20 0.39
CYP2A6 P11509 4/20 0.38
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
AOX1 Q06278 1/20 0.36
TRIM24 O15164 1/20 0.36
HPGD P15428 1/20 0.36
ALDH5A1 P51649 1/20 0.36
ABAT P80404 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
TRIM33 Q9UPN9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29818656 1.00 TYR (0.48) TYRALDH1A1ALDH1A3TSHRKDM4E
SCHEMBL26908613 0.85 ALDH1A1 (0.39) TYRALDH1A1ALDH1A3TSHRKDM4E
SCHEMBL29818670 0.83 TYR (0.48) TYRALDH1A1ALDH1A3TSHRKDM4E
SCHEMBL26908538 0.83 ALDH1A1 (0.40) TYRALDH1A1ALDH1A3KDM4EPTGS2
SCHEMBL9231758 0.83 TYR (0.52) TYRALDH1A1ALDH1A3TSHRKDM4E
SCHEMBL8031911 0.79 TYR (0.48) TYRALDH1A1ALDH1A3TSHRKDM4E
SCHEMBL10338935 0.79 LMNA (0.50) TYRALDH1A1KDM4ECYP2A6
SCHEMBL29724084 0.79 LMNA (0.50) TYRALDH1A1KDM4ECYP2A6
SCHEMBL605235 0.79 TYR (0.58) TYRALDH1A1TSHRKDM4ERAB9A
SCHEMBL15352436 0.78 ERN1 (0.52) TYRALDH1A1HSP90AA1HSP90AB1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916552-B2 Pharmaceutical combinations ASTEX THERAPEUTICS LIMITED (GB) 2014-12-23 US disclosed
US-8779132-B2 Pharmaceutical compounds ASTEX THERAPEUTICS LIMITED (GB) 2014-07-15 US disclosed
US-8277807-B2 Pharmaceutical combinations ASTEX THERAPEUTICS LIMITED (GB) 2012-10-02 US disclosed
US-20100179145-A1 PHARMACEUTICAL COMBINATIONS ASTEX THERAPEUTICS LIMITED (GB) 2010-07-15 US disclosed
US-20100152184-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2010-06-17 US disclosed
US-20100092474-A1 PHARMACEUTICAL COMBINATIONS ASTEX THERAPEUTICS LIMITED (GB) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100092474-A1 PHARMACEUTICAL COMBINATIONS HSP90AB1, HEATR6, HEATR1 TYR 1837/4885ALDH1A1 2281/4885ALDH1A3 3197/4885
US-20100152184-A1 PHARMACEUTICAL COMPOUNDS RPP30, RPLP1, NR5A1 TYR 1632/4885ALDH1A1 1780/4885ALDH1A3 1944/4885
US-20100179145-A1 PHARMACEUTICAL COMBINATIONS GSK3B, CDK1, CDK6 TYR 3403/4885ALDH1A1 3443/4885ALDH1A3 3335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.